{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:34:14Z","timestamp":1740126854691,"version":"3.37.3"},"reference-count":70,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Neurol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myasthenia gravis (MG) is an acquired autoimmune neuromuscular junction transmission disorder that clinically presents as fluctuating or persistent weakness in various skeletal muscle groups. Neuroprognostication in MG begins with some basic observations on the natural history of the disease and known treatment outcomes. Our objective is to provide a framework that can assist a clinician who encounters the MG patient for the first time and attempts to prognosticate probable outcomes in individual patients. In this review article, we explore clinical type, age of onset, antibody status, severity of disease, thymus pathology, autoimmune, and other comorbidities as prognostic factors in MG.<\/jats:p>","DOI":"10.1055\/s-0043-1775791","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T23:02:38Z","timestamp":1695769358000},"page":"799-806","source":"Crossref","is-referenced-by-count":0,"title":["Disease-Based Prognostication: Myasthenia Gravis"],"prefix":"10.1055","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2931-5597","authenticated-orcid":false,"given":"Jorge L.","family":"Almodovar","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anahit","family":"Mehrabyan","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"A Vincent","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"N E Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55","author":"A Jaretzki III","year":"2000","journal-title":"Neurology"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials","volume":"45","author":"M Benatar","year":"2012","journal-title":"Muscle Nerve"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1212\/WNL.0b013e31827b907b","article-title":"Complete stable remission and autoantibody specificity in myasthenia gravis","volume":"80","author":"F Baggi","year":"2013","journal-title":"Neurology"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"D Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1756286419832242","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"C Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ana.410140504","article-title":"Prognosis of ocular myasthenia","volume":"14","author":"C T Bever Jr","year":"1983","journal-title":"Ann Neurol"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/jnnp.52.10.1121","article-title":"The natural course of myasthenia gravis: a long term follow up study","volume":"52","author":"H J Oosterhuis","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis","volume":"60","author":"M J Kupersmith","year":"2003","journal-title":"Arch Neurol"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: response to long-term immunosuppressive treatment","volume":"62","author":"N Sommer","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"A R Punga","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1055\/s-0043-118441","article-title":"Myasthenia gravis\u2014exacerbation and crisis","volume":"02","author":"M Schroeter","year":"2018","journal-title":"Neurol Int Open"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","article-title":"Factors affecting outcome in ocular myasthenia gravis","volume":"128","author":"M Mazzoli","year":"2018","journal-title":"Int J Neurosci"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","article-title":"Clinical predictors for the prognosis of myasthenia gravis","volume":"17","author":"L Wang","year":"2017","journal-title":"BMC Neurol"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/mus.27369","article-title":"Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis","volume":"64","author":"J Vijayan","year":"2021","journal-title":"Muscle Nerve"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1532-5415.2000.tb02635.x","article-title":"Clinical characteristics and prognosis of myasthenia gravis in older people","volume":"48","author":"A Evoli","year":"2000","journal-title":"J Am Geriatr Soc"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/joim.12310","article-title":"The autoimmune spectrum of myasthenia gravis: a Swedish population-based study","volume":"277","author":"F Fang","year":"2015","journal-title":"J Intern Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"K Lazaridis","year":"2020","journal-title":"Front Immunol"},{"issue":"09","key":"ref20","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"J J Verschuuren","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"22","key":"ref21","doi-asserted-by":"crossref","first-page":"e3002","DOI":"10.1212\/WNL.0000000000010910","article-title":"Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm","volume":"95","author":"S Shelly","year":"2020","journal-title":"Neurology"},{"issue":"24","key":"ref22","doi-asserted-by":"crossref","first-page":"e2966","DOI":"10.1212\/WNL.0000000000012050","article-title":"Clinical utility of striational antibodies in paraneoplastic and myasthenia gravis paraneoplastic panels","volume":"96","author":"S Shelly","year":"2021","journal-title":"Neurology"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3233\/JND-180313","article-title":"Serum acetylcholine receptor antibodies before the clinical onset of myasthenia gravis","volume":"5","author":"E Strijbos","year":"2018","journal-title":"J Neuromuscul Dis"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1007\/s00415-021-10520-x","article-title":"Long-term outcomes and prognostic factors in generalized myasthenia gravis","volume":"268","author":"Y Ozawa","year":"2021","journal-title":"J Neurol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen3.12180","article-title":"Japanese clinical guidelines for myasthenia gravis: putting into practice","volume":"6","author":"H Murai","year":"2015","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"G I Wolfe","year":"2016","journal-title":"N Engl J Med"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"G I Wolfe","year":"2019","journal-title":"Lancet Neurol"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/nyas.13519","article-title":"Thymus involvement in early-onset myasthenia gravis","volume":"1412","author":"M A Cron","year":"2018","journal-title":"Ann N Y Acad Sci"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12016-016-8558-3","article-title":"Thymic germinal centers and corticosteroids in myasthenia gravis: an immunopathological study in 1035 cases and a critical review","volume":"52","author":"F Truffault","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"09","key":"ref30","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41379-022-01070-2","article-title":"Ectopic germinal centers in the thymus accurately predict prognosis of myasthenia gravis after thymectomy","volume":"35","author":"J Sarkkinen","year":"2022","journal-title":"Mod Pathol"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"W Hoch","year":"2001","journal-title":"Nat Med"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"E Bartoccioni","year":"2006","journal-title":"Neurology"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12883-022-02593-6","article-title":"Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes","volume":"22","author":"Q Huang","year":"2022","journal-title":"BMC Neurol"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s12883-021-02439-7","article-title":"Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study","volume":"21","author":"S Zhao","year":"2021","journal-title":"BMC Neurol"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.20069","article-title":"Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients","volume":"30","author":"L Zhou","year":"2004","journal-title":"Muscle Nerve"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"J T Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awl095","article-title":"MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis","volume":"129","author":"M E Farrugia","year":"2006","journal-title":"Brain"},{"issue":"09","key":"ref38","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"A Marx","year":"2013","journal-title":"Autoimmun Rev"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jneuroim.2008.05.032","article-title":"MuSK-antibody positive myasthenia gravis: questions from the clinic","volume":"201\u2013202","author":"D B Sanders","year":"2008","journal-title":"J Neuroimmunol"},{"issue":"10","key":"ref40","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review","volume":"89","author":"M K Hehir","year":"2017","journal-title":"Neurology"},{"issue":"02","key":"ref41","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","article-title":"Lrp4 is a receptor for Agrin and forms a complex with MuSK","volume":"135","author":"N Kim","year":"2008","journal-title":"Cell"},{"issue":"10","key":"ref42","doi-asserted-by":"crossref","first-page":"e975","DOI":"10.1212\/WNL.0000000000012463","article-title":"Characterization of LRP4\/Agrin antibodies from a patient with myasthenia gravis","volume":"97","author":"Z Yu","year":"2021","journal-title":"Neurology"},{"issue":"03","key":"ref43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mus.26985","article-title":"Clinical features of LRP4\/agrin-antibody-positive myasthenia gravis: a multicenter study","volume":"62","author":"M H Rivner","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2017.07.006","article-title":"Pathophysiology and immunological profile of myasthenia gravis and its subgroups","volume":"49","author":"F Romi","year":"2017","journal-title":"Curr Opin Immunol"},{"issue":"06","key":"ref45","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1046\/j.1468-1331.2003.00678.x","article-title":"Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study","volume":"10","author":"F Romi","year":"2003","journal-title":"Eur J Neurol"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.thorsurg.2018.12.007","article-title":"Surgical decision making: thymoma and myasthenia gravis","volume":"29","author":"G M Comacchio","year":"2019","journal-title":"Thorac Surg Clin"},{"issue":"06","key":"ref47","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/ene.14820","article-title":"Clinical characteristics and outcomes of thymoma-associated myasthenia gravis","volume":"28","author":"R \u00c1lvarez-Velasco","year":"2021","journal-title":"Eur J Neurol"},{"issue":"04","key":"ref48","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"D B Sanders","year":"2016","journal-title":"Neurology"},{"issue":"03","key":"ref49","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"P Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"J F Howard Jr","year":"2017","journal-title":"Lancet Neurol"},{"key":"ref51","first-page":"2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"T Vu","year":"2022","journal-title":"NEJM Evid"},{"issue":"06","key":"ref52","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/mus.26695","article-title":"Cross-sectional analysis of the myasthenia gravis patient registry: disability and treatment","volume":"60","author":"G Cutter","year":"2019","journal-title":"Muscle Nerve"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/mus.24697","article-title":"Mortality in myasthenia gravis: a nationwide population-based follow-up study in Denmark","volume":"53","author":"J S Hansen","year":"2016","journal-title":"Muscle Nerve"},{"issue":"39","key":"ref54","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.3346\/jkms.2021.36.e242","article-title":"Survival, prognosis, and clinical feature of refractory myasthenia gravis: a 15-year nationwide cohort study","volume":"36","author":"S Jeong","year":"2021","journal-title":"J Korean Med Sci"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jns.2007.04.045","article-title":"Myasthenic crisis: guidelines for prevention and treatment","volume":"261","author":"A Jani-Acsadi","year":"2007","journal-title":"J Neurol Sci"},{"issue":"05","key":"ref56","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.48.5.1253","article-title":"Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation","volume":"48","author":"C E Thomas","year":"1997","journal-title":"Neurology"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/mus.23445","article-title":"Myasthenic crisis patients who require intensive care unit management","volume":"46","author":"H Sakaguchi","year":"2012","journal-title":"Muscle Nerve"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","article-title":"Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients","volume":"19","author":"C Nelke","year":"2022","journal-title":"J Neuroinflammation"},{"issue":"03","key":"ref59","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","article-title":"Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases","volume":"94","author":"B Neumann","year":"2020","journal-title":"Neurology"},{"issue":"18","key":"ref60","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","article-title":"Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals","volume":"72","author":"A Alshekhlee","year":"2009","journal-title":"Neurology"},{"issue":"12","key":"ref61","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1007\/s00415-021-10603-9","article-title":"MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation","volume":"268","author":"N K\u00f6nig","year":"2021","journal-title":"J Neurol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-2-44","article-title":"Myasthenia gravis","volume":"2","author":"V C Juel","year":"2007","journal-title":"Orphanet J Rare Dis"},{"issue":"04","key":"ref63","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/mus.21195","article-title":"Juvenile myasthenia gravis","volume":"39","author":"L M Chiang","year":"2009","journal-title":"Muscle Nerve"},{"issue":"12","key":"ref64","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s10072-013-1443-4","article-title":"The effect of steroid treatment and thymectomy on bone age and height development in juvenile myasthenia gravis","volume":"34","author":"H Wang","year":"2013","journal-title":"Neurol Sci"},{"issue":"01","key":"ref65","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.athoracsur.2020.12.045","article-title":"Outcomes of juvenile myasthenia gravis: a comparison of robotic thymectomy with medication treatment","volume":"113","author":"Z Li","year":"2022","journal-title":"Ann Thorac Surg"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ene.12599","article-title":"Myasthenia gravis and risks for comorbidity","volume":"22","author":"N E Gilhus","year":"2015","journal-title":"Eur J Neurol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"117549","DOI":"10.1016\/j.jns.2021.117549","article-title":"Comorbidities worsen the prognosis of generalized myasthenia gravis post-thymectomy","volume":"427","author":"S M Laakso","year":"2021","journal-title":"J Neurol Sci"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3389\/fneur.2020.01053","article-title":"Myasthenia gravis and COVID-19: clinical characteristics and outcomes","volume":"11","author":"A E Camelo-Filho","year":"2020","journal-title":"Front Neurol"},{"issue":"12","key":"ref71","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S1474-4422(20)30413-0","article-title":"COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)","volume":"19","author":"S Muppidi","year":"2020","journal-title":"Lancet Neurol"},{"issue":"04","key":"ref72","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/mus.27497","article-title":"Clinical course and outcome of an outpatient clinic population with myasthenia gravis and COVID-19","volume":"65","author":"O Gungor Tuncer","year":"2022","journal-title":"Muscle Nerve"}],"container-title":["Seminars in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1775791.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:13:32Z","timestamp":1698970412000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1775791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":70,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2023,11,2]]},"published-print":{"date-parts":[[2023,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1775791","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0271-8235","1098-9021"],"issn-type":[{"type":"print","value":"0271-8235"},{"type":"electronic","value":"1098-9021"}],"subject":[],"published":{"date-parts":[[2023,9,26]]}}}